MaxCyte, Inc. (NASDAQ:MXCT) Short Interest Update

MaxCyte, Inc. (NASDAQ:MXCT) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 3,881,689 shares, a growth of 55.1% from the January 15th total of 2,503,062 shares. Currently, 3.8% of the shares of the company are sold short. Based on an average trading volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Based on an average trading volume of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Currently, 3.8% of the shares of the company are sold short.

MaxCyte Stock Down 1.9%

Shares of MXCT traded down $0.01 during trading hours on Monday, reaching $0.72. 1,262,423 shares of the company traded hands, compared to its average volume of 1,423,422. The stock has a fifty day simple moving average of $1.28 and a 200 day simple moving average of $1.47. MaxCyte has a fifty-two week low of $0.68 and a fifty-two week high of $4.32. The stock has a market capitalization of $76.76 million, a PE ratio of -1.64 and a beta of 1.21.

Hedge Funds Weigh In On MaxCyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirabella Financial Services LLP lifted its stake in MaxCyte by 24.2% in the third quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after acquiring an additional 1,600,000 shares during the last quarter. State Street Corp lifted its holdings in shares of MaxCyte by 4.0% during the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after purchasing an additional 91,534 shares during the last quarter. AXA S.A. grew its stake in shares of MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after purchasing an additional 1,215,481 shares during the period. Kennedy Capital Management LLC purchased a new stake in MaxCyte during the third quarter worth $3,330,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in MaxCyte during the fourth quarter valued at $1,594,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MXCT shares. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $7.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.